Addex Therapeutics Ltd ADXN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.50K | -- | -- | -- | 191.40K |
| Total Other Revenue | 66.70K | -- | -- | -- | 84.20K |
| Total Revenue | 104.20K | -- | -- | -- | 275.70K |
| Cost of Revenue | 445.70K | -- | -- | -- | 859.60K |
| Gross Profit | -341.50K | -- | -- | -- | -584.10K |
| SG&A Expenses | 2.93M | -- | -- | -- | 2.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.38M | -- | -- | -- | 3.17M |
| Operating Income | -3.27M | -- | -- | -- | -2.90M |
| Income Before Tax | -8.66M | -- | -- | -- | -6.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.66 | -- | -- | -- | -6.37 |
| Earnings from Discontinued Operations | -4.30K | -- | -- | -- | 15.83M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.66M | -- | -- | -- | 9.46M |
| EBIT | -3.27M | -- | -- | -- | -2.90M |
| EBITDA | -3.27M | -- | -- | -- | -2.68M |
| EPS Basic | -0.07 | -- | -- | -- | 0.10 |
| Normalized Basic EPS | -0.05 | -- | -- | -- | -0.04 |
| EPS Diluted | -0.07 | -- | -- | -- | 0.10 |
| Normalized Diluted EPS | -0.05 | -- | -- | -- | -0.04 |
| Average Basic Shares Outstanding | 471.68M | -- | -- | -- | 393.29M |
| Average Diluted Shares Outstanding | 471.68M | -- | -- | -- | 393.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |